Pharmacophore model generation and 3D-QSAR analysis of N-acyl and N-aroylpyrazolines for enzymatic and cellular B-Raf kinase inhibition

Medicinal Chemistry Research

Volumn 22, Issue 5, 2013, Pages 2174-2187

  Tanwar, Omprakash ^a   Marella, Akranth ^a   Shrivastava, Sandeep ^a   Mumtaz Alam, M ^a   Akhtar, Mymoona ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

3D QSAR; N acyl and N aroylpyrazolines; Pharmacophore; PHASE; Phosphodiesterases; Schr dinger

Indexed keywords

B RAF KINASE INHIBITOR; PYRAZOLINE DERIVATIVE;

ARTICLE; ELECTRON; ENZYME INHIBITION; ENZYME SYNTHESIS; HYDROPHOBICITY; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84879624037     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0210-z     Document Type: Article

References (30)

1. Ahmad T, Eisen T (2004) Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10:6388S-6392S
2. Anna MA, Marco T, Antonino L (2010) 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors. Eur J Med Chem 45:4774-4782
3. Aronov AM, Baker C, Bemis GW, Cao J, Chen G, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Martinez-Botella G, Namchuk MN, Straub J, Tang Q, Xie X (2007) Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. J Med Chem 50:1280-1287
4. Christopher B, Duffey MO, Gould AE, Kulkarni B, Liu JX, Menon S, Nagayoshi M, Vos TJ, Williams J (2010) Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors. Bioorg Med Chem Lett 20(16):4795-4799
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
6. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647-671
7. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63:5198-5202
8. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S (2006) Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66(2):999-1006
9. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23(37):6292-6298
10. LigPrep (2009) Version 2.3, Schrödinger, LLC, New York
11. MacroModel (2009) Version 9.7, Schrödinger, LLC, New York
12. Mahipal XX, Tanwar OP, Karthikeyan C, Moorthy NSHN, Trivedi P (2010) 3D-QSAR of aminophenyl benzamide derivatives as histone deacetylase inhibitors. Med Chem 6:277-285
13. Ménard D, Niculescu-Duvaz I, Dijkstra HP, Niculescu-Duvaz D, Suijkerbuijk BM, Zambon A, Nourry A, Roman E, Davies L, Manne HA, Friedlos F, Kirk R, Whittaker S, Gill A, Taylor RD, Marais R, Springer CJ (2009) Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. J Med Chem 52:3881-3891
14. Muddassar M, Pasha FA, Yoo KH, Lee SH, Cho SJ (2008) Docking and quantum mechanics-guided CoMFA analysis of b-RAF inhibitors. Bull Korean Chem Soc 29:1499-1504
15. Niculescu-Duvaz I, Roman E, Whittaker SR, Friedlos F, Kirk R, Scanlon IJ, Davies LC, Niculescu-Duvaz D, Marais R, Springer CJ (2008) Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold. J Med Chem 51:3261-3274
16. Pasha FA, Srivastava HK, Beg Y, Singh PP (2006) DFT based electrophilicity index and QSAR study of phenols as anti Leukaemia agent American. J Immunol 2(1):23-28
17. Pasha FA, Muddassar M, Neaz MM, Cho SJ (2009) Pharmacophore and docking-based combined in silico study of KDR inhibitors. J Mol Graph Model 28:54-61
18. Ramurthy S, Subramanian S, Aikawa M, Amiri P, Costales A, Dove J, Fong S, Jansen JM, Levine B, Ma S, McBride CM, Michaelian J, Pick T, Poon DJ, Girish S, Shafer CM, Stuart D, Sung L, Renhowe PA (2008) Design and synthesis of orally bioavailable Benzimidazoles as Raf kinase inhibitors. J Med Chem 51:7049-7052
19. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26(22):3291-3310
20. Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9:180-186
21. Sachin SN, Mariam SD (2007) Pharmacophore refinement and 3D-QSAR studies of histamine H3 antagonists. QSAR Comb Sci 26:744-753
22. Samantha L, Cesare M, Aleksey K, Mattia S, Stefano M, Elena C, Dorotea R, Alessandro C (2008) SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease. Bioorg Med Chem 16:5695-5703
23. PHASE-3.1, Schrödinger, LLC (2009) New York
24. Shah UA, Deokar HS, Kadam SS, Kulkarni VM (2010) Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl)pyrimidines as COX-2 inhibitors. Mol Divers 14:559-568
25. Singh PP, Srivastava HK, Pasha FA (2004) DFT-based QSAR study of testosterone and its derivatives. Bioorg Med Chem 12:171-177
26. Srivastava HK, Pasha FA, Mishra SK, Singh PP (2009) Novel applications of atomic softness and QSAR study of testosterone derivatives. Med Chem Res 18:455-466
27. Tanwar OP, Saha R, Alam MM, Akhtar M (2010) 3D-QSAR of amino-substituted pyrido[3,2B]pyrazinones as PDE-5 inhibitors. Med Chem Res. doi: 10.1007/s00044-010-9523-y
28. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105(8):3041-3046
29. Viney L, Rajendra K, Jagmohan SS, Rajendra K, Narasingapuram AK, Vitukudi NB (2008) QSAR models for prediction of glycogen synthase kinase-3b inhibitory activity of indirubin derivatives. QSAR Comb Sci 27:718-728
30. Zambon A, Ménard D, Suijkerbuijk BM, Niculescu-Duvaz I, Whittaker S, Niculescu-Duvaz D, Nourry A, Davies L, Manne HA, Lopes F, Preece N, Hedley D, Ogilvie LM, Kirk R, Marais R, Springer CJ (2010) Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors. J Med Chem 53:5639-5655